List of communications


Relevance of pro-angiogenic factors secretion in glioblastoma patients

García-Romero Noemí1, IMDEA Nanoscience, Madrid, Spain; Carrión-Navarro Josefa2, Fundación Hospital de Madrid-IMMA, Madrid, Spain; Esteban-Rubio Susana3, Universidad San Pablo CEU, Madrid, Spain; Zafra-Villaverde Antonio4, Universidad San Pablo CEU, Madrid, Spain; Prat-Acín Ricardo, Hospital Universitario la Fe, Valencia, Spain; Fernández-Carballal Carlos, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Belda-Iniesta Cristobal5, Fundación Hospital de Madrid-IMMA, IMDEA Nanoscience, Madrid, Spain; Ayuso-Sacido Angel6, Fundación Hospital de Madrid-IMMA, IMDEA Nanoscience, Universidad San Pablo-CEU, Madrid, Spain.


BACKGROUND

Glioblastoma multiforme (GBM) is the most prevalent glial tumor, characterized by its heterogeneous population, aggressiveness and poor prognosis. Despite the advances on the surgical approaches in combination with new radio- and/or chemo-therapies the prognosis remains dismal. An important feature of GBM development is the need of new blood vessels that support their maintenance and growth. In this regard, a new generation of small molecules as well as monoclonal antibodies to block angiogenesis have been approved for the treatment of solid tumors. Bevacizumab, a recombinant human monoclonal antibody that neutralizes VEGF-A biological activity, preventing the binding to its receptors in the surface of endothelial cells, and reducing tumor neo-angiogenesis, has proven successful in clinical trials against different tumors like ovarian cancer but the results have been controversial for GBM.

RESULTS AND CONCLUSION

We have evaluated the VEGF-A expression level of three established glioma cell lines, either in vitro or in vivo. Further, we have design cell-specific bevacizumab treatments, for all three cell lines assayed, based on their basal secretion of VEGF-A, in both normoxic and hypoxic conditions. Our data indicate an optimal bevacizumab dose should be established for each patient to improve the treatment outcomes.

Format: Poster

Organized by